Elutia lines up new financing for NXT-41x, backs FDA timelines

Elutia Inc. reported second quarter 2026 results on August 13, 2026 and said it arranged new financing tied to its NXT-41x program. The company continues to expect FDA clearance for NXT-41 in the fourth quarter of 2026 and for NXT-41x in the first half of 2027.¹ Elutia said it recently held a productive meeting with the FDA on the NXT-41 submission, which remains on track.¹

On the survey front, an independent market research firm conducted a blinded survey of 50 board-certified plastic and reconstructive surgeons across 28 states, who average 11.6 years in practice and perform about 140 complex reconstructive procedures annually.¹ 86% reported that matrices used today increase infection risk, with a 95% confidence interval of 74 to 93%.¹ 96% rated the rifampin and minocycline combination effective, with 64% calling it extremely effective, and no respondents rated it ineffective.¹

On financing, Elutia arranged up to $26 million in additional capital, structured as a $15 million credit facility with $10 million funded at closing and $5 million more available after NXT-41x clearance, plus up to $11 million tied to the SimpliDerm sale, including $8 million in cash at closing and up to $3 million contingent on technology transfer and commercial milestones.¹ The company also expects to receive the remaining $8 million held in escrow from the 2025 BioEnvelope divestiture, with release anticipated in the fourth quarter of 2026.¹

Elutia said this financing, combined with the divestitures, is meant to carry the company through NXT-41x clearance and into its first full year of commercial launch in 2028.¹ Cash and equivalents stood at $19.9 million as of June 30, 2026.¹ The SimpliDerm sale, signed July 16, 2026, is expected to close in the third quarter of 2026.¹